

# Amendment Tool

v1.4 30 Nov 2020

For office use

QC: No

## Section 1: Project information

Short project title*:	REMAP-CAP			
IRAS project ID* (or REC reference if no IRAS project ID is available):	237150			
Sponsor amendment reference number*:	AM025			
Sponsor amendment date* (enter as DD/MM/YY):	05 March 2021			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>Increase in patient number from 1000 to 6000. Addition of interventions to the anticoagulation domain: Conventional low dose thromboprophylaxis, intermediate thromboprophylaxis and continuation of therapeutic dose anticoagulation (only if therapeutic doses were started on the ward. We are adding a new domain, the ACE2 RAS domain which includes the addition of 9 IMPs (all used from normal hospital stock). I have also made the below changes to the MHRA CTA. We are adding 9 IMP product to the MHRA CTA. These IMPs will be used from normal hospital stock.</p> <p>The addition of 5 ACEi Drugs: Ramipril, Lisinopril, Perindopril, Elanopril, Captopril. The addition of 4 ARB Drugs: Losartan, Valsartan, Candesartan, Irbesartan</p>			
Project type (select):	<input checked="" type="radio"/> Specific study <input type="radio"/> Research tissue bank <input type="radio"/> Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<input checked="" type="radio"/> NHS/HSC REC <input type="radio"/> Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England <input checked="" type="radio"/>	Wales <input type="radio"/>	Scotland <input type="radio"/>	Northern Ireland <input type="radio"/>
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the Combined Ways of Working (CWoW) pilot?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study receive Pharmacy Assurance?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve prisoners OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Which nations had participating NHS/HSC organisations prior to this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Which nations will have participating NHS/HSC organisations after this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

## Section 2: Summary of change(s)

What do you want to update?:	<input checked="" type="radio"/> Project information <input type="radio"/> New site/PI only
------------------------------	--

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, tick the "Add another change" box.

Change 1				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Substantial changes (e.g. affecting safety or the scientific value of the trial)			
Further information (free text - note that this field will adapt to the amount of text entered):	Addition of the ACE2 /RAS domain. We are adding a new domain where patients will be randomised to receive one of up to three renin-angiotensin system (RAS) blockade strategies, depending on availability and acceptability, or control. This includes an Angiotensin converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB). I have also made the below changes to the MHRA CTA. We are adding 9 IMP product to the MHRA CTA. These IMPs will be used from normal hospital stock.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Substantial changes (e.g. affecting safety or the scientific value of the trial)			
Further information (free text - note that this field will adapt to the amount of text entered):	Addition of interventions in the Anticoagulation domain: 1. Conventional low dose thromboprophylaxis 2. intermediate thromboprophylaxis 3. Continuation of therapeutic dose anticoagulation (only in those who already had therapeutic doses on the ward)			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 3				
Area of change (select)*:	CTIMP IMP			
Specific change (select - only available when area of change is selected first)*:	IMP being added to the study for the first time			
Further information (free text - note that this field will adapt to the amount of text entered):	I have also made the below changes to the MHRA CTA. We are adding a total of 9 IMP product to the MHRA CTA. These IMPs will be used from normal hospital stock. The addition of 5 ACEi Drugs; Ramipril Lisinopril Perindopril Enalapril Captopril			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 4	
Area of change (select)*:	CTIMP IMP

Specific change (select - only available when area of change is selected first)*:	Change of IMPs			
Further information (free text - note that this field will adapt to the amount of text entered):	I have also made the below changes to the MHRA CTA. We are adding a total of 9 IMP product to the MHRA CTA. These IMPs will be used from normal hospital stock. The addition of 4 ARB Drugs: Losartan Valsartan Candesartan Irbesartan			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 5				
Area of change (select)*:	Participant Procedures			
Specific change (select - only available when area of change is selected first)*:	Recruitment - Change in identification, approach, recruitment or consent of participants			
Further information (free text - note that this field will adapt to the amount of text entered):	We are increasing our recruitment target from 1000 to 6000 Patients			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☐

### Section 3: Declaration(s) and lock for submission

<b>Declaration by the Sponsor or authorised delegate</b>	
<ul style="list-style-type: none"> <li>I confirm that the Sponsor takes responsibility for the completed amendment tool</li> <li>I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf</li> </ul>	
Name [first name and surname]*:	Lorraine Parker
Email address*:	l.e.parker@umcutrecht.nl

<b>Lock for submission</b>  <p><b>Please note:</b> This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.</p> <div style="text-align: center; margin: 10px 0;"> <div style="background-color: #76b82a; color: white; padding: 5px 20px; display: inline-block; border: 1px solid black;">Lock for submission</div> </div> <p>After locking the tool, <a href="#">proceed to submit the amendment online</a>. The "Submission Guidance" tab provides further information about the next steps for the amendment.</p>
---

### Section 4: Review bodies for the amendment

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

Review bodies																
UK wide:					England and Wales:				Scotland:				Northern Ireland:			
Patent Authority A - Medicines	Patent Authority A - Devices	C	ation Assurance	U Governance	MCA		S	and HCRW Approval	AWIA		RAEC	al coordinating function	REC	Data Guardians	is	al coordinating function

	REC	Com MHR	Com MHR	ARS	Rad	UKS	REC	CAG	HMP	HRA	REC	PBPI	SPS	Natio	HSC	HSC	Priso	Natio	Category:
Change 1:	Y	Y				Y				(Y)				(Y)				(Y)	A
Change 2:	Y	Y				Y				(Y)				(Y)				(Y)	A
Change 3:	Y	Y				Y				Y				Y				Y	A
Change 4:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 5:	Y	N				Y				Y				Y				Y	A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	A																		